MINNEAPOLIS, May 01, 2018 -- Neuroplasticity-based brain training should change the medical treatment of psychiatric disorders, according to a keynote lecture to be delivered tomorrow by Dr. Michael Merzenich at the University of Minnesota Medical School, in a joint presentation to the Cognitive Training Institute and Psychiatry Grand Rounds. Dr. Merzenich is Professor Emeritus at University of California San Francisco and is Co-Founder of Posit Science, the developer of BrainHQ online brain training.
Dr. Merzenich is widely credited with the discovery that the brain remains plastic – capable of chemical, physical, and functional change from sensory and other inputs – throughout life. He was the first to harness plasticity to improve the human condition – through his co-invention of the cochlear implant, which converts sound waves into electrical neural inputs, restoring hearing to 100,000s of people living with deafness.
In recent years, Dr. Merzenich pioneered the development of a novel type of computerized brain training, which harnesses the brain’s inherent plasticity to improve cognitive performance, and which has been assessed in more than 100 peer-reviewed studies.
Researchers have found that training results in better performance in standard measures of cognition (e.g., speed, attention, memory); in standard measures of quality of life (e.g., mood, confidence, health-related quality of life); and in real world activities (e.g., balance, driving, instrumental activities of daily living).
That brain training has been commercialized by Posit Science, available online at www.BrainHQ.com and as Apple and Android apps, to improve cognitive and real world performance in healthy adults.
Dr. Merzenich’s keynote will focus on the further evolution of brain training in addressing seemingly intractable brain disorders. The talk will include a review of research study results in addressing mental illnesses (e.g., depression, schizophrenia, bipolar); brain injuries (e.g., stroke, TBI, chemobrain); and neurodegenerative diseases (e.g., dementia, Parkinsons, MS). Dr. Merzenich will also discuss how apps will be used to monitor and manage brain health across the lifespan.
Dr. Merzenich has been elected to both the National Academy of Sciences and the National Academy of Medicine. He also is a recipient of the Russ Prize (the highest honor in bio-engineering) from the National Academy of Engineering. In addition, he is a Kavli Laureate in Neuroscience (the highest honor in that field).
For more information, contact: [email protected]


Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 



